Pharmacokinetics of meloxicam in healthy Chinese volunteers

Yaoxue Xuebao

Volumn 36, Issue 1, 2001, Pages 73-

  Xu, Hai Yan ^a   Zhong, Da Fang ^a   Zhao, Li Mei ^b   Zhang, Yi Fan ^a   Zhang, Bao Jun ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Drug metabolic polymorphism; Meloxicam; Pharmacokinetics

Indexed keywords

EID: 0042838270     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Noble S, Balfour JA. Meloxicam: new drug profile [J]. Drugs, 1996, 51(3): 424-430.
2. Chesne C, Guyomard C, Guillouzo A, et al. Metabolism of meloxicam in human liver involves cytochromes P4502C9 and 3A4 [J]. Xenobiotica, 1998, 28 (1): 1-13.
3. Sullivan-Klose TH, Ghanayem BI, Bell DA, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism [J]. Pharmacogenetics, 1996, 6(2): 341-349.
4. Xu HY, Li XQ, Sun L, et al. HPLC Method for determination of meloxicam in human plasma [J]. J Shenyang Pharm Univ (in Chinese), In press.
5. Zhuang CQ. Applied Basis of Statistics [M]. Guangzhou: South China University of Science and Engineering Publishing House, 1992. 275-277.
6. Schmid J, Busch U, Heinzel G, et al. Pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects [J]. Drug Metab Dispos, 1995, 23(11): 1206-1213.
7. Tuerck D, Busch U, Heinzel G, et al. Clinical pharmacokinetics of meloxicam [J]. Arzneimittelforsch, 1997, 47(3): 253-258.